company background image
BGD

Biogened WSE:BGD Stock Report

Last Price

zł14.10

Market Cap

zł34.6m

7D

3.7%

1Y

62.1%

Updated

29 Sep, 2022

Data

Company Financials
BGD fundamental analysis
Snowflake Score
Valuation2/6
Future Growth0/6
Past Performance5/6
Financial Health3/6
Dividends0/6

BGD Stock Overview

Biogened S.A. develops, produces, and distributes pharmaceutical products in Poland.

Biogened S.A. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Biogened
Historical stock prices
Current Share Pricezł14.10
52 Week Highzł16.00
52 Week Lowzł8.00
Beta0.69
1 Month Change-8.44%
3 Month Change11.91%
1 Year Change62.07%
3 Year Change78.48%
5 Year Change12.89%
Change since IPO-64.75%

Recent News & Updates

Jun 29
Is Biogened (WSE:BGD) A Risky Investment?

Is Biogened (WSE:BGD) A Risky Investment?

The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...

Shareholder Returns

BGDPL PharmaceuticalsPL Market
7D3.7%0.8%-7.9%
1Y62.1%-1.8%-35.7%

Return vs Industry: BGD exceeded the Polish Pharmaceuticals industry which returned -0.4% over the past year.

Return vs Market: BGD exceeded the Polish Market which returned -33.1% over the past year.

Price Volatility

Is BGD's price volatile compared to industry and market?
BGD volatility
BGD Average Weekly Movement12.1%
Pharmaceuticals Industry Average Movement5.5%
Market Average Movement6.1%
10% most volatile stocks in PL Market11.7%
10% least volatile stocks in PL Market3.8%

Stable Share Price: BGD is more volatile than 90% of Polish stocks over the past 3 months, typically moving +/- 12% a week.

Volatility Over Time: BGD's weekly volatility (12%) has been stable over the past year, but is still higher than 75% of Polish stocks.

About the Company

FoundedEmployeesCEOWebsite
n/a185Andrzej Grzegorzewskihttps://www.biogened.pl

Biogened S.A. develops, produces, and distributes pharmaceutical products in Poland. The company offers dermo-cosmetic products under the Dermedic brand. It also exports its products.

Biogened S.A. Fundamentals Summary

How do Biogened's earnings and revenue compare to its market cap?
BGD fundamental statistics
Market Capzł34.63m
Earnings (TTM)zł3.66m
Revenue (TTM)zł72.20m

9.5x

P/E Ratio

0.5x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
BGD income statement (TTM)
Revenuezł72.20m
Cost of Revenuezł26.06m
Gross Profitzł46.13m
Other Expenseszł42.48m
Earningszł3.66m

Last Reported Earnings

Jun 30, 2022

Next Earnings Date

Nov 14, 2022

Earnings per share (EPS)1.49
Gross Margin63.90%
Net Profit Margin5.06%
Debt/Equity Ratio49.8%

How did BGD perform over the long term?

See historical performance and comparison

Dividends

1.4%

Current Dividend Yield

13%

Payout Ratio